Treatment Options with Integrative Chiropractic for Migraines

Learn about the advantages of chiropractic integrative treatment for managing and reducing migraine frequency.

Abstract

This educational post provides a deep dive into the modern landscape of migraine, a complex and often misunderstood neurological disorder. From my perspective as a clinician with a diverse background in chiropractic (DC), nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), I will guide you through understanding migraine’s true impact. We will explore its epidemiology, the critical steps for accurate diagnosis, and the intricate physiological mechanisms driving the condition. The discussion will highlight the latest findings from leading researchers, focusing on the roles of the hypothalamus, the trigeminovascular system, and key neurotransmitters like calcitonin gene-related peptide (CGRP) and serotonin (5-HT). We will unpack how these discoveries have revolutionized both acute and preventive treatments.

We will also move from the cellular level of nerve transmission—exploring the SNARE complex and SNAP-25 proteins—to the practical use of cutting-edge medications like OnabotulinumtoxinA (Botox), ditans (lasmiditan), and gepants (ubrogepant, rimegepant, atogepant). We will also examine the groundbreaking CGRP antagonist therapies, including oral gepants and injectable monoclonal antibodies, alongside standard-of-care oral medications. This post will detail our unique, multidisciplinary approach at Injury Medical Clinic PA, where my collaboration with our medical director, Dr. Maria Guadalupe Cardenas, MD, allows us to integrate advanced chiropractic care, functional medicine, and conventional medical oversight to create personalized and effective treatment plans for our patients, helping them move beyond pain and reclaim their lives.

Our Collaborative and Integrative Practice in El Paso, Texas

Before we dive into the complexities of migraine, I want to share our clinical philosophy and the unique structure of our practice at Injury Medical Clinic PA (also widely recognized as Mission Plaza Injury Medical Clinic) in El Paso, Texas. My name is Dr. Alex Jimenez, and my journey in healthcare has led me to accumulate a range of specializations, including a Doctorate in Chiropractic (DC) and credentials as an Advanced Practice Registered Nurse (APRN) and a Board-Certified Family Nurse Practitioner (FNP-BC). My passion for understanding the root causes of chronic disease also drove me to become a Certified Functional Medicine Practitioner (CFMP), certified through the Institute for Functional Medicine (IFMCP), and to pursue further training in advanced topics in neurology (ATN) and clinical competency in spine and trauma (CCST). You can explore my clinical observations and ongoing research further at wellnessdoctorrx.com and my professional network on LinkedIn at https://www.linkedin.com/in/dralexjimenez/.

This diverse training allows me to view patient health through multiple lenses—structural, neurological, metabolic, and systemic. However, the cornerstone of our clinic’s success and our ability to provide comprehensive care lies in our collaborative model. I am honored to work alongside Dr. Maria Guadalupe Cardenas, MD, our Medical Director and Collaborative Physician. Dr. Cardenas is a highly respected, board-certified Internist with over four decades of profound clinical experience. Her extensive medical knowledge and compassionate approach to patient care provide the essential medical oversight that anchors our integrative practice. Her NPI number is 1164426749, and she is licensed to practice medicine in Texas under license number J2933.

This multidisciplinary setup, where a Medical Doctor provides medical direction for a team that includes a Doctor of Chiropractic and other healthcare professionals, is a powerful model for modern healthcare, particularly in the realms of injury and chronic pain management. At our clinic, this collaboration allows us to blend seamlessly:

• Medical Oversight (Dr. Cardenas): Providing diagnostic leadership, managing pharmacological interventions when necessary, evaluating cardiovascular risk factors, and ensuring all treatments meet the highest medical standards.
• Chiropractic and Neuromusculoskeletal Care (Dr. Jimenez): Focusing on spinal health, nervous system function, biomechanics, and structural integrity through adjustments, mobilization, and other manual therapies.
• Functional Medicine: Investigating the underlying root causes of illness, such as nutritional deficiencies, hormonal imbalances, gut health, and environmental triggers.
• Personal Injury and Rehabilitation: Creating customized programs to help patients recover from accidents and injuries, restore function, and reduce pain.
• Advanced Diagnostics and Therapies: Utilizing modern, evidence-based tools to inform our personalized treatment plans.

By integrating these disciplines, we don’t just treat symptoms; we treat the whole person. This is particularly crucial for complex conditions like migraine, which, as you will see, involves a web of genetic, neurological, and environmental factors. Our goal is to empower our patients with the knowledge and tools they need to reclaim their health, and this comprehensive, team-based approach is how we achieve it.

Understanding the Widespread Impact of Migraine

When we think about common health issues, conditions like diabetes or high blood pressure often come to mind. Yet, migraine is a disorder of staggering prevalence that frequently flies under the radar. The statistics are eye-opening and underscore why a deeper understanding matters for clinicians and patients alike.

• Global Prevalence: More than a billion people across the globe suffer from migraine. This makes it one of the most common neurological diseases worldwide.
• Gender Disparity: The condition disproportionately affects women, with studies showing that one in five women will experience migraine in their lifetime, compared to one in sixteen men.
• Impact on Children: Migraine is not just an adult problem. It affects approximately one in eleven children. Interestingly, before the onset of puberty and hormonal changes (menarche), the prevalence is roughly equal between boys and girls. Only after puberty does the significant female predominance emerge.
• Household Impact: The ripple effects of this condition are immense. It’s estimated that one in four households in the United States includes someone who suffers from migraine.

These numbers paint a clear picture: migraine is not a rare or niche complaint. It is a widespread public health issue. If I looked around a typical waiting room with about twenty people, the odds are high that at least three or four of them are grappling with this condition.

So, who is on the front lines of caring for this vast population? It’s not primarily neurologists or specialized headache centers. The vast majority—an estimated 70% of people with migraine—are managed in the primary care setting. This places immense responsibility on primary care providers, nurse practitioners, physician assistants, and even clinicians like me in the chiropractic and functional medicine fields, who often see these patients first. We must be equipped with the knowledge to identify migraine accurately, rule out more sinister causes of headache, and offer a broad spectrum of safe and effective treatments. We must stay current on the latest research to provide the best possible care for this underserved population.

How to Identify and Diagnose Migraine: Beyond the Stereotype

One of the greatest challenges in managing migraine is its chameleon-like nature. The public and even many healthcare professionals hold a stereotyped image of a migraine patient: a young woman in her late twenties or early thirties, lying in a dark room with a severe headache that coincides with her menstrual cycle. While this presentation is certainly common, it is far from the only one.

Migraine can, and does, affect anyone. The man in the photo on this slide is a perfect example—he is older, and men are often overlooked when it comes to a migraine diagnosis. In my clinical experience, men frequently endure their symptoms for years, often not seeking help until the condition becomes debilitating and profoundly impacts their work and family life. They may dismiss their headaches as “stress” or “sinus” issues, delaying a correct diagnosis.

Furthermore, the symptoms themselves are not monolithic. While many associate migraine with the classic aura—the reversible neurological symptoms like seeing flashing lights that precede the headache—only about 30% of people with migraine experience it. The pain itself, the location, and the associated symptoms can vary dramatically from person to person, and even from one attack to another in the same individual.

This variability is why we must approach every patient with an open mind and a systematic diagnostic process. We need to be alert to the nuances that distinguish migraine from other headache disorders and, most importantly, from secondary headaches that signal a more dangerous underlying condition. Before we can discuss treatment, our first and most critical job is to listen carefully and ask the right questions.

The SNOOP Mnemonic: Red Flags We Cannot Afford to Miss

Before diagnosing a primary headache disorder like migraine, our foremost responsibility is to rule out a secondary headache, which is a headache caused by another underlying medical condition. Some of these conditions can be life-threatening, so a vigilant and systematic approach is non-negotiable. A helpful tool I use and teach is the SNOOP mnemonic, which outlines the critical red flags that demand further investigation, often with neuroimaging and referral to a higher level of care.

S: Systemic Symptoms or Secondary Risk Factors

• Systemic Symptoms: When a patient presents with a headache accompanied by other constitutional symptoms like fever, unexplained weight loss, or myalgias (muscle aches), we must think beyond a simple migraine. These symptoms could indicate an underlying infection, such as meningitis, or an inflammatory condition. The headache is part of a larger, systemic process that needs to be identified and treated.
• Secondary Risk Factors: A patient’s medical history is paramount. If the person presenting with a new or different headache has a history of cancer, HIV, or is pregnant, our index of suspicion for a secondary cause must be high. For example, in a cancer patient, we must consider the possibility of metastatic disease to the brain. In pregnancy, a new-onset headache could be a sign of a serious condition like cerebral venous thrombosis or pre-eclampsia.

N: Neurologic Signs or Symptoms

• This is one of the most critical red flags. If a patient’s headache is accompanied by any focal neurologic deficit—such as weakness on one side of the body, new-onset confusion, difficulty speaking, or a seizure—this is an emergency. Similarly, if a fundoscopic exam reveals papilledema (swelling of the optic disc), it suggests increased intracranial pressure, which could be caused by a tumor, bleed, or other serious pathology. These patients require immediate imaging and evaluation in an emergency setting.

O: Onset

• The way a headache begins tells us a great deal. A headache with a sudden, or “thunderclap,” onset is a classic warning sign of subarachnoid hemorrhage. This headache goes from zero to the worst pain imaginable in seconds to minutes. It is unlike a typical migraine, which tends to build in intensity over a period of time. Even though a migraine attack can awaken someone from sleep with severe pain, it typically has a waxing and waning quality—it builds, may ease slightly, and then intensifies again. A true thunderclap headache is a singular, explosive event.

O: Older Age of Onset

• Most primary headache disorders, including migraine, begin in adolescence or early adulthood. Therefore, a new headache after age 50 should always be thoroughly investigated. A key concern in this age group is giant cell arteritis (also known as temporal arteritis). This inflammatory blood vessel condition, if left untreated, can lead to blindness. Clues include tenderness over the temples, jaw claudication (pain with chewing), and sometimes associated weight loss.

P: Pattern Change, Precipitated by Action, Positional, or Papilledema

• Pattern Change: If a patient with a long-standing, stable migraine pattern comes in and says, “This is different,” we must listen. For example, a woman I’ve been treating for menstrual migraine for years who suddenly develops a persistent, daily headache—even if it’s not severe—needs re-evaluation. A significant change in headache frequency, severity, or character warrants neuroimaging to rule out new intracranial pathology.
• Precipitated by Action: Headaches that are triggered exclusively by the Valsalva maneuver—actions that increase intra-abdominal and intracranial pressure like coughing, sneezing, or bearing down—are a major red flag. This can suggest a space-occupying lesion, such as a tumor or a Chiari malformation, that obstructs cerebrospinal fluid flow.
• Positional: A headache that changes dramatically with body position strongly suggests a pressure dysregulation issue. The classic example is a low-pressure headache (spontaneous intracranial hypotension), where the headache is severe when the person is upright (sitting or standing) but is completely or almost completely relieved by lying down flat. Conversely, a headache that is worse when lying down could indicate high intracranial pressure.
• Sexual Activity: Headaches associated with sexual activity, particularly an explosive headache at the point of orgasm (orgasmic headache), function similarly to a Valsalva-induced headache and require the same level of concern for an underlying vascular or structural issue.

By methodically working through the SNOOP criteria with every patient presenting with a headache, we can confidently distinguish those who can be safely managed in our clinic from those who require urgent medical intervention.

The Diagnostic Criteria for Migraine: A Closer Look

Once we rule out red flags, our next step is to determine whether the patient’s symptoms align with the formal diagnostic criteria for migraine. The International Classification of Headache Disorders (ICHD-3) provides the globally accepted framework. Let’s break down the criteria for the most common form, migraine without aura.

To receive a diagnosis, a patient must have had at least five headache attacks that meet the following criteria. Each attack must last between 4 and 72 hours if untreated or unsuccessfully treated.

The headache itself must have at least TWO of the following four characteristics (often remembered by the acronym PUMA):

1. P – Pulsating Quality: The pain is often described as throbbing, pounding, or pulsing. It feels like it’s in sync with the heartbeat.
2. U – Unilateral Location: The pain is typically located on one side of the head. The side can shift between attacks, or it can start on one side and spread to become bilateral.
3. M – Moderate to Severe Intensity: The pain is significant enough to interfere with or prohibit daily activities. This is not a mild, background headache; it commands the person’s attention.
4. A – Aggravation by Routine Physical Activity: This is a key distinguishing feature. Simple movements like walking up a flight of stairs, bending over, or even going from sitting to standing will make the headache worse.

In addition to the pain characteristics, during the headache, the patient must experience at least ONE of the following:

1. Nausea and/or Vomiting: This is a very common and distressing symptom. Many people with migraine feel a profound sense of sickness in their stomach.
2. Photophobia (light sensitivity) AND Phonophobia (sound sensitivity): During an attack, ordinary levels of light and sound can become intensely painful and intolerable, forcing the person to retreat to a dark, quiet room.

What makes diagnosing migraine so tricky is the “two of the four” and “one of the two” rule. This means that presentations can vary widely. For instance:

• A patient with a bilateral, non-throbbing pressure headache that is moderate in severity and worsened by movement, accompanied by nausea, officially meets the criteria for migraine. Many people (and clinicians) might incorrectly label this a “tension headache” because it’s bilateral and feels like pressure.
• Another patient might have a unilateral, throbbing headache of mild-to-moderate intensity that doesn’t stop them from working, but they experience significant light and sound sensitivity. This also qualifies as a migraine.

The key takeaway is that we cannot rely on a single symptom, like throbbing pain or unilateral location, to make the diagnosis. We must consider the entire constellation of symptoms. A migraine can exist on a spectrum, from a moderately disruptive headache to a completely incapacitating attack that confines someone to bed for days. The specific symptoms present can even vary from one attack to the next for the same individual. Recognizing this variability is the first step toward accurate diagnosis and effective management.

The PIN Screener: A Quick and Powerful Tool for Primary Care

While the formal ICHD-3 criteria are the gold standard for diagnosis, they can be cumbersome in a busy clinical setting. This is where a simple, rapid screening tool can be incredibly valuable. Dr. Richard Lipton, a leading neurologist and headache epidemiologist, developed the ID Migraine™ screener based on his extensive research. It’s a validated three-question tool that uses the acronym PIN.

The three questions are:

1. P – Photophobia: “During a headache, are you bothered by light?”
2. I – Impairment: “Has a headache limited your ability to work, study, or do what you needed to do for at least one day in the last three months?”
3. N – Nausea: “When you have a headache, do you feel nauseated or sick to your stomach?”

The scoring is straightforward: if a patient answers “yes” to two out of these three questions, there is a 93% positive predictive value that they have migraine. This is, of course, assuming that the more serious red flags (SNOOP) have already been ruled out.

I find this tool to be exceptionally useful in my practice. It’s quick, easy to remember, and cuts through a lot of the symptomatic noise. It focuses on three of the most common and debilitating features of migraine: sensory sensitivity, functional disability, and gastrointestinal distress. When a patient comes in complaining of “bad headaches,” I often start by running through the PIN questions. A positive screen gives me a high degree of confidence that we are dealing with migraine and allows me to move forward with a more detailed history and treatment plan. It’s a powerful example of how evidence-based research can be translated into a practical clinical tool that improves diagnostic accuracy.

Migraine vs. Tension-Type Headache: A Critical Distinction

One of the most frequent diagnostic errors in clinical practice is mislabeling a migraine as a tension-type headache. While both are primary headache disorders, their underlying mechanisms, clinical features, and treatments are quite different. Understanding these differences is crucial for providing effective care. Let’s compare and contrast the key features.

Feature	Migraine	Tension-Type Headache
Duration	4–72 hours in adults (can be shorter, ~2 hours, in children)	30 minutes to 7 days (more variable)
Location	Often unilateral (one-sided), but can be bilateral (~40% of cases)	Always bilateral (both sides)
Pain Quality	Pulsating or throbbing (~50% of the time); can also be pressure	Pressing or tightening (non-pulsating); like a band around the head
Intensity	Moderate to severe; often disabling	Mild to moderate; usually not disabling
Aggravation by Activity	YES. Worsened by routine physical activity (e.g., climbing stairs)	NO. Not worsened by routine activity; may even improve with gentle movement
Associated Symptoms	Nausea and/or vomiting; Both photophobia and phonophobia	None or only one of the following: mild photophobia or mild phonophobia (but not both)
The single most powerful question to differentiate between the two is: “Does routine physical activity aggravate your headache?”

If a patient tells me that walking up a flight of stairs or bending over makes their head pound, my suspicion for migraine skyrockets. In contrast, someone with a tension-type headache often feels better if they get up, stretch their neck, and move around after sitting at a computer or driving for a long time. This is because tension-type headache is often linked to pericranial muscle tension. For a person with migraine, that same activity would be agonizing.

It’s also worth noting that patients with tension-type headaches rarely present to a doctor’s office seeking urgent care; they can typically manage their symptoms at home with over-the-counter medications or lifestyle adjustments. When a patient’s headache is severe enough to prompt a clinic visit, we should always think migraine first, especially without red flags. Getting this diagnosis right is the foundation of a successful treatment plan.

The Full Migraine Attack: It’s More Than Just a Headache

The pain of a migraine headache is often the most dramatic and disabling part of an attack, but it’s crucial to understand that it is just one piece of a larger, multi-phase neurological event. A full migraine attack can span several days and involves a sequence of distinct phases. As clinicians, asking our patients about their experience before and after the pain can provide valuable diagnostic clues and help them understand the full scope of their condition.

The Interictal Phase

This is the period between migraine attacks. For some, this phase is completely symptom-free. For those with chronic migraine, this phase may be very short or non-existent. A key part of our history-taking is quantifying how many truly headache-free days a person has each month. This helps us gauge disorder severity and track treatment effectiveness.

The Prodrome Phase (The “Warning” Stage)

Occurring hours to a day or two before the headache pain begins, the prodrome is experienced by up to 70% of people with migraine. These are non-painful premonitory symptoms that signal an attack is on its way. They stem from changes in the brain, particularly in the hypothalamus. Common prodromal symptoms include:

• Mood changes: Irritability, depression, or euphoria.
• Cognitive difficulties: Trouble concentrating, word-finding difficulty (“brain fog”).
• Increased sensory sensitivity: Heightened sensitivity to light, sound, or smells.
• Fatigue and yawning.
• Neck stiffness: A very common and often misinterpreted symptom. Many patients believe their “tension headache” in their neck causes their migraine, when in fact, the neck stiffness is part of the migraine prodrome itself, originating in the brain.
• Food cravings or fluid retention.

The Aura Phase

Experienced by about 30% of migraine sufferers, the aura consists of a set of fully reversible, transient neurological symptoms that typically precede or sometimes accompany the headache. An aura usually develops over 5-20 minutes and lasts for less than 60 minutes.

• Visual Aura: This is the most common type. It is typically a positive phenomenon, meaning something is added to the visual field. Patients may describe seeing shimmering lights, zig-zag lines (fortification spectra), spots, or stars. It often starts in the center of the visual field and expands outward. This differs from the visual loss (negative phenomenon) seen in a transient ischemic attack (TIA), which is more like a curtain coming down over the field of vision.
• Sensory Aura: Numbness or tingling, often starting in the fingertips and migrating up the arm to the face.
• Language Aura: Transient aphasia or difficulty speaking.

The Headache Phase (The “Pain” Stage)

This is the phase most people associate with migraine. It lasts from 4 to 72 hours and includes the characteristic pain (throbbing, unilateral, moderate-to-severe) and associated symptoms (nausea, vomiting, photophobia, phonophobia) that we’ve discussed. During this phase, the patient is often incapacitated and seeks rest in a dark, quiet environment.

The Postdrome Phase (The “Migraine Hangover”)

After the worst of the head pain subsides, the attack is still not over for many. The postdrome phase can last for another 24-48 hours. Patients often describe feeling:

• Exhausted and fatigued.
• Cognitively impaired or “drained.”
• Sore and achy, with tenderness of the scalp and neck muscles.
• Sudden head movements can still cause a brief jolt of pain.

Educating our patients about these phases empowers them. They learn to recognize the prodrome, which can give them a crucial window to take acute medication or implement non-pharmacological strategies to lessen the severity of the impending attack. Understanding the postdrome also helps them be patient with themselves and plan for a day of rest and recovery after an attack, rather than feeling frustrated by their lingering “hangover” symptoms. It validates their experience that a migraine is a whole-body, multi-day event, not just a few hours of head pain.

The Pathophysiology of Migraine: Unraveling the Brain’s Electrical and Chemical Storm

To truly understand how to treat migraine effectively, we must first appreciate the complex science of what is happening inside the brain during an attack. For a long time, migraine was thought to be a purely vascular problem—vasoconstriction followed by rebound vasodilation causing pain. We now know this is a gross oversimplification. Migraine is a primary neurological disorder with a strong genetic basis, involving a complex interplay of electrical and chemical events in the brain. We can conceptualize this in two main categories: central mechanisms and peripheral mechanisms.

Central Mechanisms: The Brain’s “Migraine Generator”

The journey of a migraine attack begins deep within the brain, long before any pain is felt.

• Genetic Predisposition: First and foremost, migraine is highly heritable. Research suggests that if you have a first-degree relative with migraine, your risk is significantly increased. In my practice, I always ask about family history, and in about 70% of my migraine patients, I can identify at least one other blood relative with the trait. This tells us that some individuals are born with a brain that is inherently more sensitive or “hyperexcitable.”
• The Role of the Hypothalamus: Mounting evidence points to the hypothalamus as a key “generator” or initiator of migraine attacks. Located in the diencephalon, the hypothalamus is a master regulatory center in the brain. It controls a vast array of functions, including the sleep-wake cycle, appetite, hormone regulation, and body temperature. It also serves as a critical hub for processing sensory information coming into the brain. It is no coincidence that highly stressful emotional events, sleep deprivation, or missed meals can trigger a migraine. Our emotions are deeply woven into this neurobiological web. Leading researchers have identified that in individuals who suffer from migraines, there is a certain “wonkiness”—a functional dysmodulation or hypersensitivity—within this specific region of the brain. The brain of a migraineur is fundamentally hyper-excitable. It processes sensory information differently than the brain of someone who does not suffer from migraines.

• • The prodromal symptoms we discussed earlier—fatigue, yawning, food cravings, mood changes—are all classic hypothalamic functions. Functional MRI (fMRI) studies have shown hypothalamic activation up to 48 hours before headache pain begins. This suggests that dysregulation, or a “storm,” in the hypothalamus is one of the earliest events in the migraine cascade. It helps explain why triggers like lack of sleep, stress, or skipping a meal can provoke an attack, as these all disrupt the homeostatic balance that the hypothalamus strives to maintain.

• Cortical Spreading Depression (CSD): The Basis of Aura: For the 30% of patients who experience aura, the neurological basis is a phenomenon called cortical spreading depression (CSD). This is a slow-moving, self-propagating wave of intense neuronal and glial depolarization (a burst of electrical activity) that spreads across the surface of the cerebral cortex at a rate of about 3-5 mm per minute. This intense activity is followed by a prolonged period of neuronal suppression or silence.

• • If this wave moves across the visual cortex at the back of the brain, it produces the characteristic visual aura (e.g., shimmering lights).
  • If it moves across the somatosensory cortex, it produces the tingling and numbness of a sensory aura.
  • The CSD wave itself is not painful. However, it is a powerful activator of the next phase of the migraine attack.

Peripheral Mechanisms: The Trigeminal Nerve and CGRP

The CSD wave and other central triggers activate a critical pain pathway in the brain: the trigeminovascular system. This is where the pain of migraine is generated.

1. Activation of the Trigeminal Nerve: The trigeminal nerve (cranial nerve V) is the largest cranial nerve and is responsible for sensation in the face and head. Its nerve endings densely innervate the meninges, the protective membranes surrounding the brain, and the blood vessels that lie within them. To understand the physiological underpinnings, we must look at the specific structures this nerve supplies: the dura mater (the tough, outermost layer of the meninges) and the cerebral blood vessels. The first division of this nerve, the ophthalmic division (V1), plays a major role, supplying the forehead, eye, and these crucial pain-sensitive structures. When activated by central triggers like CSD, these trigeminal nerve endings become sensitized.
2. Release of Inflammatory Neuropeptides: This activation causes the trigeminal nerve endings to release a cocktail of inflammatory neuropeptides directly onto the meningeal blood vessels. The most important and well-studied of these is calcitonin gene-related peptide (CGRP). Other players include Substance P and neurokinin A.
3. The Role of CGRP: CGRP is a potent vasodilator (it causes blood vessels to widen) and is a key player in transmitting pain signals. We know definitively that the trigeminal system is activated and CGRP is released en masse during a migraine attack. Modern evidence-based research has proven this through peripheral vascular measurements. If we draw blood from the jugular vein of a patient during an active migraine attack, we will find that the levels of this particular neurotransmitter are significantly elevated. Conversely, if we measure their blood between attacks, the CGRP levels return to a lower baseline. CGRP release leads to a state known as neurogenic inflammation. This process involves:

• • Vasodilation: The meningeal blood vessels swell.
  • Plasma Protein Extravasation: The vessels become leaky, allowing plasma proteins to seep into the surrounding tissue and cause further inflammation and irritation.
  • Mast Cell Degranulation: This releases even more inflammatory substances, including histamine, prostaglandins, and cytokines. This brings more inflammatory molecules “into the party,” effectively keeping the localized inflammation going and creating a vicious cycle: inflammation stimulates the nerve, the nerve releases more CGRP, and the CGRP causes more inflammation.

• Pain Signal Transmission: Inflamed, throbbing blood vessels and a chemical soup of inflammatory mediators bombard trigeminal nerve endings with pain signals. These signals travel from the periphery back along the trigeminal nerve to a relay station in the brainstem called the trigeminal nucleus caudalis (TNC). The TNC sits strategically at the top of the cervical spinal cord and the lower medulla, acting as the grand tollbooth for sensory information entering from the head and neck. From the TNC, second-order neurons take these bundled impulses and relay them to the hypothalamus. Here, the pathophysiology becomes highly complex: if the trigeminal nerve is strongly stimulated, the signal is sent to the hypothalamus. Because the hypothalamus in a migraineur is already overstimulated, it overreacts and fires off more impulses than it should, sending them into the thalamus (the brain’s primary sensory relay station) and then up into the sensory cortex. When the signal reaches the cortex, the individual consciously perceives pain.
• Central Sensitization: If the barrage of pain signals from the periphery is intense and sustained, the neurons in the TNC and thalamus can become hyperexcitable and hyperresponsive. This state is called central sensitization.

• • Central sensitization is the reason why, during a bad migraine attack, stimuli that are not normally painful become painful. This is called allodynia. Patients will report that simply touching their scalp, brushing their hair, or resting their head on a pillow is excruciatingly painful. This is also why light and sound sensitivity become so extreme. The entire central nervous system is on high alert, amplifying every incoming sensory signal.

This modern understanding—from the central generator in the hypothalamus, through CSD and the activation of the trigeminovascular system, to the pivotal role of CGRP and the development of central sensitization—has been revolutionary. It has shifted our focus from simply constricting blood vessels to targeting the specific neurological pathways and chemical messengers involved in the attack. This has paved the way for highly specific and effective treatments, which we will explore next.

Understanding Nerve Fiber Transmission in Migraines

CGRP expression varies by the type of nerve fiber it inhabits, which helps explain the different types of pain patients experience during an attack.

• C-Fibers: CGRP is abundantly found in C-fibers. These are unmyelinated (lacking an insulating sheath) nerve fibers that transmit electrical impulses relatively slowly. Because of this slow transmission, stimulation of C-fibers produces the deep, dull, aching, and throbbing pain that can persist for days during a migraine.
• Alpha-Delta Fibers (A-Delta Fibers): CGRP also functions as a receptor on A-delta fibers, as well as on surrounding glial cells (the support cells of the nervous system). A-delta fibers are thinly myelinated, allowing them to conduct impulses much faster. This rapid firing and quick transmission are responsible for the sharp, acute, piercing pains that often accompany the onset of a migraine.

By understanding the physiological differences between these fibers, our multidisciplinary team can better target treatments, whether through fast-acting pharmacological agents overseen by Dr. Cardena, or neuromodulatory chiropractic techniques that aim to downregulate these hyperactive pain pathways.

Defining the Goals of Modern Migraine Treatment

When a patient comes to me suffering from migraines, our initial conversation always centers on their goals. The ultimate aim, of course, is to achieve freedom and a full return to normal function. These two objectives are inextricably linked. It’s not enough to reduce the pain if the patient is still unable to work, care for their family, or enjoy their life.

In migraine management, we clearly distinguish between two types of care: acute treatment goals and preventive treatment goals. Just as with any chronic disorder—whether it is hypertension, diabetes, or autoimmune disease—you absolutely must have a comprehensive, personalized plan developed for every single person dealing with migraines.

Acute Treatment Goals

The primary goal of an acute treatment plan is rapid headache relief and restored function. When a patient feels the prodrome or the aura of a migraine coming on, time is of the essence. In our clinical practice, I firmly believe it is unacceptable to evaluate someone for a headache disorder and not clearly discuss exactly what they need to do at the very onset of an attack.

Preventive Treatment Goals

Deciding when to start preventive therapy is crucial. It’s a common misconception that preventive treatment is reserved only for those with frequent, debilitating attacks. However, even if someone experiences a migraine just once a month—perhaps predictably with their menstrual cycle or another known trigger—the disability it causes warrants proactive treatment.

The American Headache Society provides guidelines that help us structure this decision-making process.

• High-Impact, Infrequent Attacks: If a patient has even one or two attacks per month that are intensely disabling, preventive therapy should be a primary consideration.
• Moderate Frequency: For individuals experiencing two to four migraine attacks per month, the intensity of the attacks helps determine the need for prevention. We weigh the level of disability and disruption against the potential benefits and side effects of daily medication.
• High Frequency: If a patient has attacks between four and six times a month, regardless of pain intensity, it becomes essential to offer and strongly consider preventive therapy. At this frequency, the cumulative impact on quality of life is significant.

The primary goals of any preventive strategy are threefold:

1. Reduce the frequency of migraine attacks.
2. Reduce pain intensity when an attack does occur.
3. Reduce the duration of each attack.

By achieving these goals, we not only lessen the burden of the disease but also reduce thepatient’ss reliance on acute medications, which brings its own benefits and lowers the risk of complications like medication overuse headache.

Crafting a Personalized Toolkit for Acute Migraine Treatment

With the vast array of acute migraine treatments available today, patients often feel overwhelmed. The key to success is not finding a single “magic bullet,” but stratifying care and creating a personalized “toolkit” in close collaboration with the patient. This involves a detailed conversation about the nature of their different headaches.

Many of my patients can distinguish between headache types. They might say, “If the headache starts on both sides of my head and feels like a dull pressure, I know it’s probably not going to be a full-blown migraine. I can take an over-the-counter anti-inflammatory and be okay.” In contrast, they might also report, “But if the pain starts behind my left eye with a sharp, throbbing quality, I know I’m in trouble. That’s the one that will lead to severe nausea and vomiting, and I need to use my prescription medication immediately.”

This kind of nuanced information helps us build an effective, tiered treatment plan.

The Stratified Care Model

• For Mild Pain:

• • Treatment: A simple analgesic is often sufficient. This typically includes a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen or naproxen, or acetaminophen.
  • Clinical Considerations: Before recommending these, we must always assess the patient’s risk factors. Does the patient have a history of peptic ulcer disease or gastrointestinal bleeding? Do they have renal disease? Is their hypertension well-controlled? NSAIDs can exacerbate these conditions, so a thorough medical history, often reviewed in conjunction with Dr. Cardenas, is paramount.

• For Moderate Pain:
  • Treatment: This is where we introduce migraine-specific agents. These are medications designed to target the underlying pathophysiology of a migraine attack. The most common classes include:

• • • Triptans (e.g., sumatriptan, rizatriptan)
    • Ergotamines (e.g., DHE 45)
    • Ditans (e.g., lasmiditan)

• • Clinical Considerations: Medication choice depends heavily on the patient’s cardiovascular health. When I began my practice over 30 years ago, my migraine patients were often in their twenties or early thirties with few vascular risk factors. Today, my patient population has aged with me, and many now have hypertension, coronary artery disease, or other vascular issues. Triptans and ergotamines cause vasoconstriction and are contraindicated in patients with a history of stroke, uncontrolled hypertension, or significant vascular disease. We also must be mindful of comorbid medications, particularly those that interact with the CYP3A4 enzyme system, as many migraine drugs are metabolized through this pathway. Dr. C. Cardenas’s 40 years of experience as an internist is invaluable here. She meticulously evaluates each patient’s cardiovascular history, ensuring that the pharmacotherapy we choose is not only highly effective but impeccably safe.
• For Severe Pain:
  • Treatment: We can use a migraine-specific agent, often in a more potent, faster-acting formulation (like an injection). To enhance its effect and manage associated symptoms, we often add a dopamine antagonist.

• Examples include metoclopramide, chlorpromazine, or promethazine.

• • Clinical Rationale: These adjunctive medications serve two purposes. First, they are powerful anti-emetics, providing relief from the severe nausea and vomiting that often accompany intense migraines. Second, they appear to boost the pain-fighting power of the primary migraine-specific agent, leading to more comprehensive and rapid relief.

Innovations in Standard Acute Therapies: New Formulations of Old Friends

The field of migraine treatment is constantly evolving, not just with new molecules but with innovative delivery systems for established medications. These new formulations can dramatically improve the patient experience by speeding onset, improving tolerability, or bypassing issues like nausea-induced gut stasis.

The Triptan Family: Evolving Since 1991

The triptan class has been the workhorse of acute migraine therapy since sumatriptan was first introduced. Sumatriptan, the first in its class, is a perfect example of how formulations have evolved to meet different patient needs. It is available as a standard oral tablet, a subcutaneous injection, and a nasal spray. Recently, we’ve seen even more advanced options come to market.

• Subcutaneous Sumatriptan: The standard dose has long been a 6 mg auto-injector. While highly effective, some patients experience side effects like chest tightness or nausea. A 3 mg auto-injector is now available, which I find very useful for patients who benefit from the rapid action of an injection but struggle with the side effects of the higher dose. It often provides the right balance of efficacy and tolerability.
• Nasal Formulations:

• • Nasal Spray with Permeation Enhancer: A new nasal spray includes a permeation enhancer, a compound that helps the drug cross the nasal mucosa more efficiently. This leads to better, more consistent absorption than older nasal spray formulations.
  • Breath-Activated Nasal Powder: Another exciting innovation is a nasal powder. The patient exhales into the device to prime it, then inhales the powder. This breath-powered delivery system achieves excellent absorption rates and can be a preferred option for many.

• Triptan-NSAID Combination: A new combination product containing rizatriptan (a triptan) and meloxicam (a long-acting NSAID) has recently become available. The concept of combining a triptan with an NSAID is not new, but previous products were pulled from the market due to lackluster efficacy. The clinical trials for this new combination look very promising. The synergy between the migraine-specific action of the triptan and the NSAID’s broad anti-inflammatory effect appears to provide more robust, sustained relief for many patients.

Dihydroergotamine (DHE 45): A Powerful Tool Made More Accessible

DHE 45 is a potent and effective ergotamine derivative that has been a go-to treatment for severe, refractory migraines, particularly in emergency and inpatient settings. However, its use in the outpatient setting was historically limited by its cumbersome delivery method. It came in a glass ampule, requiring the patient to break the ampule, draw the medication into a syringe, and then self-administer the injection—a daunting task for anyone, let alone someone in the midst of a severe migraine attack.

Excitingly, DHE 45 has been released in a modern auto-injector in recent months. This has been a game-changer, making this powerful therapy far more accessible and practical for outpatient use. It provides a rapid onset of action for severe migraine.

As a side note, this new DHE 45 auto-injector is also an excellent option for patients with cluster headache, another severe primary headache disorder, further expanding its clinical utility. DHE 45 is also available as a propellant-based nasal spray, and diclofenac is available as a liquid solution, which can provide a very quick onset of action for those with moderate pain who may not be candidates for vasoconstrictive medications.

The Mechanism of Action: Understanding How Acute Migraine Drugs Work

To choose the right medication, we need to understand how these different drug classes interact with the complex pathophysiology of a migraine. The three main classes of modern, migraine-specific acute therapies are the triptans, the ditans, and the gepants.

The Inverse Relationship Between Serotonin and CGRP: How Triptans Work

Another major player in migraine neurochemistry is serotonin (5-hydroxytryptamine, or 5-HT). Serotonin and CGRP have a fascinating and clinically vital inverse relationship. When serotonin levels in the synaptic cleft are elevated, CGRP release is actively inhibited, and its levels drop.

Triptans are 5-HT1B/1D receptor agonists.

• Mechanism: They work presynaptically (on the transmitting neuron) to mimic the action of serotonin at these specific receptor subtypes. By agonizing these receptors, they inhibit the release of CGRP, a potent pro-inflammatory neuropeptide central to migraine pain. This action helps to quell the neurogenic inflammation that characterizes a migraine attack.
• The Downside: Vasoconstriction: The 5-HT1B receptor is also found on the smooth muscle of blood vessels, particularly cranial arteries. Triptan activation of this receptor causes vasoconstriction. This is the reason for the black box warnings and contraindications for their use in patients with uncontrolled hypertension, coronary artery disease, a history of stroke or transient ischemic attack (TIA), or other significant peripheral vascular disorders.

Ditans (Lasmiditan): A Nuanced Approach to the Serotonin System

The development of the ditan class represents a significant step forward in separating the desired therapeutic effect from the unwanted vasoconstrictive side effects. Lasmiditan is the first and only drug in this class.

• Mechanism: Lasmiditan is also a serotonin agonist, but it is highly selective for the 5-HT1F receptor. It still works presynaptically to block the release of CGRP, effectively short-circuiting the migraine cascade.
• The Key Advantage: No Vasoconstriction. The crucial difference is that the 5-HT1F receptor is not located on vascular smooth muscle. Therefore, lasmiditan achieves its therapeutic effect without causing vasoconstriction. This makes it an invaluable option for patients who respond well to serotonin-based therapy but have cardiovascular contraindications to triptans. For example, a patient who had excellent relief from sumatriptan for years but has since developed poorly controlled hypertension can now safely use lasmiditan to treat their acute attacks.

Gepants: A Postsynaptic Blockade of CGRP

The gepants represent a completely different mechanism of action, targeting the CGRP pathway directly but from the other side of the synapse. They are CGRP receptor antagonists.

• Mechanism: Instead of preventing CGRP release (like triptans and ditans), gepants work postsynaptically. They sit on and block the CGRP receptor on the receiving neuron. This means that even if CGRP is released into the synapse, it cannot bind its receptor or trigger the downstream signaling cascade that leads to pain and inflammation. Think of it as putting a cover over the keyhole so the CGRP “key” cannot get in.
• The Advantage: Targeted and Non-Vascular: Because they do not interact with serotonin or adrenergic receptors, gepants do not cause vasoconstriction and are safe for patients with cardiovascular disease.

Deep Dive into the New Acute Classes: Gepants and Ditans

These newer classes have transformed our ability to treat acute migraine, offering effective and safer options for a broader range of patients. Let’s explore their specific characteristics, advantages, and disadvantages.

The Gepants: Ubrogepant, Rimegepant, and Zavegepant

There are currently three gepants on the market for acute treatment: ubrogepant and rimegepant (oral tablets) and the newly approved zavegepant (nasal spray).

Key Advantages of Gepants:

• No Risk of Medication Overuse Headache (MOH): This is a monumental advantage. MOH is a debilitating condition where the very medication used to treat acute attacks, when taken too frequently, begins to cause more frequent headaches. MOH is defined as using:

• • Triptans, ergots, opioids, or combination analgesics on 10 or more days per month.
  • Simple analgesics (like NSAIDs or acetaminophen) on 15 or more days per month.

• Gepants have been studied extensively and do not appear to cause this paradoxical increase in headache frequency. This makes them an excellent choice for patients with high-frequency episodic or chronic migraine who are at high risk for MOH.

• Not Controlled Substances: Unlike some older combination analgesics containing butalbital, gepants are not scheduled substances, which simplifies prescribing.

Disadvantages and Clinical Considerations:

• CYP3A4 Metabolism: Gepants are heavily metabolized by the CYP3A4 enzyme in the liver. This requires careful screening of the patient’s full medication list for potential drug-drug interactions.

• • Inducers: Some medications, like the anticonvulsant topiramate (which is ironically also used for migraine prevention), are CYP3A4 inducers. They speed up the enzyme’s activity, causing the gepant to be metabolized and cleared from the body more quickly. If a patient is taking topiramate, I may need to use a higher dose of the gepant to achieve a therapeutic effect. For instance, with ubrogepant, which comes in 50 mg and 100 mg strengths, I would likely choose the 100 mg dose for a patient on topiramate.
  • Inhibitors: Other medications, like the calcium channel blocker verapamil (also used for headache prevention) or certain antibiotics and antifungals, are CYP3A4 inhibitors. They slow down the enzyme, leading to higher-than-expected blood levels of the gepant and an increased risk of side effects. In these cases, a lower dose of gepant may be necessary, or the combination may need to be avoided altogether.

• New Warnings (Hypertension and Raynaud’s): Post-marketing surveillance has identified rare but important potential side effects. There have been reports of new-onset hypertension or aggravation of pre-existing hypertension, as well as new-onset or worsening of Raynaud’s phenomenon. While these are uncommon, counsel patients on these risks and monitor them accordingly, especially those with pre-existing vascular sensitivities.

The Ditan: Lasmiditan

As mentioned, lasmiditan is the sole member of the ditan class. Its unique profile gives it a specific and valuable place in our treatment algorithm.

Disadvantages and Clinical Considerations:

• Central Nervous System (CNS) Side Effects: Lasmiditan readily crosses the blood-brain barrier, which can lead to significant CNS side effects. The most common are dizziness, paresthesia (tingling sensations), and somnolence (drowsiness).
• Driving Restriction: Due to the potential for profound dizziness and sedation, patients are strictly advised not to drive or operate heavy machinery for at least 8 hours after taking a dose. This is a major practical limitation for many people.
• Schedule V Medication: Lasmiditan is classified as a Schedule V controlled substance, indicating a low potential for abuse, but this still adds a layer of regulatory and prescribing complexity.

Clinical Positioning of Lasmiditan:

Given these characteristics, where do I position lasmiditan in my practice? I find it is an excellent choice for a patient experiencing a severe migraine attack, particularly in the evening or when they can be at home and rest. Its potent somnolence can be used to our therapeutic Advantage. For many migraine sufferers, sleep is a powerful abortive. By inducing sleep, lasmiditan not only treats the underlying migraine pathophysiology but also helps the patient use their own body’s natural restorative process to break the attack. I often tell patients, “This is the medication advantage when you can put on your pajamas, get into bed, and let the medicine work while you sleep it off.”

Clinical Pearls for Optimizing Acute Treatment

Navigating acute treatment options requires skill and flexibility. Here are some practical pearls I’ve gathered over years of clinical practice:

• If a triptan isn’t fully effective: Don’t give up on it immediately. Try combining it with an NSAID or a dopamine antagonist (like metoclopramide) to boost its efficacy.
• If a patient has side effects from a triptan:

• • Switch to another one. Triptans are not all the same. Some, like naratriptan, eletriptan, and almotriptan, tend to be gentler and better tolerated.
  • Decrease the dose. As with subcutaneous sumatriptan, dropping from 6 mg to 3 mg can often preserve efficacy while eliminating side effects.

• If the headache recurs after initial treatment: This is common, where the medication works initially, but the headache returns a few hours later.

• • Add an NSAID with a long half-life, like naproxen, at the same time as the triptan. The triptan provides rapid relief, while naproxen kicks in later to help prevent recurrence.
  • Switch to a triptan with a longer half-life, such as naratriptan or frovatriptan. These are particularly useful for predictable, long-lasting migraines, such as menstrual migraine, which can persist for up to 72 hours. A long-acting triptan can provide sustained control throughout this vulnerable period.

• If the patient has significant nausea or vomiting, an oral medication is unlikely to be effective. The gut often goes into a state of stasis during a migraine attack, meaning nothing is being absorbed. In these cases, we must consider a non-oral route:

• • Nasal spray (triptan, DHE, or zavegepant)
  • Subcutaneous injection (sumatriptan or DHE)

• If there’s excessive use of acute medication: If you identify that a patient is using their acute medications on 10 or more days per month (for triptans, opioids, etc.) or 15 or more days per month (for simple analgesics), it is a critical red flag. This is the time to have a serious conversation about medication overuse and strongly advocate for starting preventive therapy.
• If standard therapies fail or are contraindicated: If a patient has tried and failed multiple triptans, has cardiovascular contraindications, or cannot tolerate them, consider newer mechanisms: a gepant (ubrogepant, rimegepant) or a ditan (lasmiditan).

Shifting Gears: The Critical Role of Preventive Therapy

While effective acute treatment is essential, the true path to freedom from migraine lies in prevention. The conversation about starting preventive therapy should be a collaborative one, guided by several key questions.

When Do We Prescribe Prevention?

1. Patient Desire: First and foremost, as nurse practitioners and clinicians, our guiding principle is shared decision-making. The question is simple: “Do you want to consider a preventive medication?”
2. Impact on Daily Life: Does migraine interfere with your daily routine? Are you missing work? Can you not drive the carpool? Are you backing out of social commitments? If yes, prevention is warranted.
3. Acute Medication Use: Is the patient overusing their acute medicines? Are they experiencing adverse effects? Prevention can reduce this reliance.
4. Frequency: As we’ve established, if a patient has four or more migraine days a month, it strongly indicates the need to initiate preventive therapy. A key distinction is the difference between episodic and chronic migraine:

• • Episodic Migraine: Headache on fewer than 15 days per month.
  • Chronic Migraine: Headache on 15 or more days per month, with at least 8 of those days having migrainous features, for at least 3 months.

The world of migraine prevention is undergoing a seismic shift. For decades, our options were limited to “borrowed” drugs—medications originally developed for other conditions that were serendipitously found to help with migraines. The last several years have ushered in the era of migraine-specific preventive therapies designed from the ground up to target the CGRP pathway. A 2024 physician consensus statement argued that these newer, targeted therapies should be considered first-line options, rather than being held back until after patients have failed multiple older medications. A 2022 position statement from the National Headache Foundation reinforces this, stating that clinicians should choose preventive therapy with the patient, based on individual needs, rather than following a rigid, one-size-fits-all algorithm.

The Presynaptic Dance: Vesicles, the SNARE Complex, and Neurotransmitter Release

To understand how some of the most advanced preventive treatments work, we must first journey back into the microscopic space between our nerve cells—the synapse. Imagine a nerve ending, or a presynaptic terminal, as a bustling harbor. Tiny packages, known as vesicles, are filled with chemical messengers called neurotransmitters (like CGRP and Substance P). To send a signal, the vesicle must dock at the edge of the nerve terminal before releasing its cargo. A group of specialized proteins manages this docking process.

One key player is a protein called SNAP-25 (Synaptosomal-Associated Protein 25). Think of SNAP-25 as part of the construction crew that builds the docking platform. It works with other proteins to form the SNARE complex. This complex acts like a molecular zipper or a set of grappling hooks, pulling the vesicle right up against the presynaptic membrane and holding it in place. Once the vesicle is securely docked, it fuses with the membrane and releases its neurotransmitters into the synaptic cleft. This entire process is fundamental for all nerve communication.

OnabotulinumtoxinA (Botox): A Targeted Intervention for Chronic Migraine

Now, let’s explore what happens when we introduce a therapeutic agent like OnabotulinumtoxinA, more commonly known as Botox, which was FDA-approved for chronic migraine in 2010.

How Botox Disrupts the Migraine Signal

The mechanism of OnabotulinumtoxinA is remarkably precise. It acts as a molecular saboteur. When injected, the neurotoxin is taken up by the nerve endings. Inside the nerve terminal, its primary mission is to find and destroy the SNAP-25 protein. The neurotoxin molecule essentially cleaves, or cuts, the SNAP-25 protein. By breaking this critical component, it becomes impossible for the nerve to build the SNARE complex. Without a functional dock, the vesicles carrying CGRP and Substance P cannot anchor to the presynaptic membrane. They are left floating within the nerve terminal, unable to fuse and release their inflammatory contents. The result is a powerful and localized shutdown of neurotransmission in both sensory and motor nerves.

The PREEMPT Protocol: A Standardized Injection Paradigm

The use of OnabotulinumtoxinA for chronic migraine follows a well-researched and standardized protocol known as PREEMPT (Phase 3 Research Evaluating Migraine Prophylaxis Therapy). This evidence-based paradigm ensures consistent, effective delivery, involving 31 injections across seven specific head-and-neck muscle groups every 12 weeks. These include the corrugator, procerus, frontalis, temporalis, occipitalis, cervical paraspinal, and trapezius muscles.

The CGRP Revolution: Monoclonal Antibodies and Gepants for Prevention

While OnabotulinumtoxinA offered a significant advancement, the last decade has ushered in a new era of migraine prevention centered around CGRP. We have now developed two distinct classes of medications designed to interrupt this specific interaction: monoclonal antibodies and gepants.

Monoclonal Antibodies (mAbs): Large Molecules with Specific Targets

These are not traditional chemical drugs; they are large, lab-engineered proteins designed to function like your body’s own antibodies but with a highly specific target.

• Ligand-Targeting mAbs: When a monoclonal antibody like eptinezumab, fremanezumab, or galcanezumab is introduced into the body, it circulates and binds directly to the CGRP ligand (the molecule itself). This binding physically alters the shape of the CGRP molecule, preventing it from fitting into its receptor. They “mop up” the CGRP before it has a chance to bind.
• Receptor-Targeting mAb: The exception in this class is erenumab. Unlike the others, erenumab does not target the CGRP ligand. Instead, it targets and blocks the CGRP receptor itself, physically preventing CGRP from binding.

Gepants: Small Molecules with a Big Impact

The second class of CGRP antagonists is the gepants. These are small-molecule drugs. The currently available gepants for prevention, such as atogepant and rimegepant, work by directly targeting and blocking the CGRP receptor, similar to erenumab. Because they are small molecules, they have different pharmacological properties, such as shorter half-lives and oral routes of administration.

A Comparative Look at Modern Migraine Preventives

The choice between these groundbreaking medications often depends on factors like administration method, dosing frequency, and patient comorbidities.

Medication	Dose	Route of Administration	Frequency	Site of Action
Eptinezumab	100 mg or 300 mg	Intravenous (IV)	Every 3 Months	Ligand
Fremanezumab	225 mg	Subcutaneous (SQ)	Monthly or Quarterly (675 mg)	Ligand
Galcanezumab	240 mg (loading dose), then 120 mg	Subcutaneous (SQ)	Monthly	Ligand
Erenumab	70 mg or 140 mg	Subcutaneous (SQ)	Monthly	Receptor
Rimegepant	75 mg	Oral (ODT)	Every Other Day	Receptor
Atogepant	10-60 mg	Oral	Daily	Receptor

Key Distinguishing Features and Clinical Considerations

• Route and Frequency: The most notable difference is eptinezumab (IV quarterly). The other mAbs are self-administered subcutaneous (SQ) injections, given monthly or quarterly (fremanezumab). The gepants (rimegepant, atogepant) are oral tablets taken daily or every other day. This offers options to suit patient preference.
• Pharmacokinetic Advantage of mAbs: A significant advantage of monoclonal antibodies is their metabolism. They bypass the liver’s cytochrome P450 (CYP) system, so they have very limited drug-drug interactions. This makes them an exceptionally safe choice for patients on complex medication regimens.
• DuaAdvantageBenefit of Rimegepant (Nurtec ODT): Rimegepant has a unique advantage: it is used for both preventive (every other day) and acute treatment (as needed), simplifying therapy for many patients.
• Side Effects of mAbs: Injection site reactions are common. A specific and noteworthy side effect associated with erenumab is constipation, so I tend to avoid it as a first-line mAb for patients with a history of IBS or chronic constipation. Eptinezumab can sometimes cause URI-like symptoms or nausea.
• Side Effects of Gepants: The most common side effects of atogepant are nausea, constipation, and somnolence.

Important New Safety Information on CGRP Antagonists

As responsible clinicians, we must stay abreast of the latest post-marketing surveillance data. In late 2025 and early 2026, new information emerged from reports to the FDA concerning CGRP antagonists as a class (both mAbs and gepants).

The FDA has received reports of two primary adverse events:

1. New Onset or Worsening of Hypertension
2. New Onset or Worsening of Raynaud’s Phenomenon

It is critical to put this into perspective. These events are uncommon, but their potential occurrence warrants attention and requires diligent blood pressure monitoring and patient education on the signs of Raynaud’s phenomenon.

Standard of Care Oral Preventive Therapies

While the new therapies are revolutionary, it’s essential to remember the traditional oral medications, which can be strategically chosen based on patient comorbidities.

• Level A Evidence (Established Efficacy):

• • Antiepileptic Drugs: Topiramate, Divalproex Sodium
  • Beta-Blockers: Propranolol, Metoprolol, Timolol
  • Angiotensin II Receptor Blocker (ARB): Candesartan

• Level B Evidence (Probably Effective):

• • Antidepressants: Amitriptyline (a tricyclic), Venlafaxine (an SNRI)
  • Beta-Blockers: Atenolol, Nadolol

• Level C Evidence (Possibly Effective):

• • Cyproheptadine, an antihistamine, can be a very effective and well-tolerated preventive strategy in children and adolescents.

Clinical Pearls for Tailoring Migraine Prevention

The art of medicine lies in personalizing treatment. Here are some clinical pearls I use to guide my decision-making for preventive therapy:

• Migraine + Hypertension: An antihypertensive like a beta-blocker (propranolol) or candesartan is a logical choice.
• Migraine + Depression or Anxiety: An antidepressant like amitriptyline or venlafaxine can be an excellent first-line option.
• Migraine + Insomnia: A low-dose tricyclic antidepressant like amitriptyline at bedtime can tackle both issues.
• Migraine in Women of Childbearing Age: Certain medications, especially valproic acid and topiramate, must be avoided due to their teratogenic effects. Thorough counseling on contraception is imperative.
• Migraine + Obesity: Topiramate can be a strategic choice, as one of its well-known side effects is weight loss.

Integrative Chiropractic Care: A Foundational Component of Migraine Management

In our practice, managing migraines goes beyond pharmacology. I believe in a whole-person approach, and integrative chiropractic care plays a vital role. Migraines are not just a chemical event; they are a neurovascular phenomenon deeply intertwined with the musculoskeletal system, particularly the cervical spine.

The trigeminal nerve has extensive connections with the upper cervical spine, forming the trigemino-cervical complex (TCC). At this convergence point, the brain processes sensory information from the head, face, and neck. Cervical dysfunction can easily trigger or amplify the central migraine generator.

• Cervicogenic Contribution: Many migraine sufferers have significant neck pain and stiffness. Misalignments, or subluxations, in the upper cervical vertebrae can irritate the surrounding nerves. With precise, gentle chiropractic adjustments, I can restore proper motion to these joints, reduce nerve irritation, and decrease the afferent (incoming) pain signals sent to the brainstem. For many patients, this reduction in “background noise” from the neck can significantly raise their migraine threshold.
• Myofascial Release: Chronic postural strain can lead to tight, painful trigger points in the muscles of the head, neck, and shoulders. These trigger points can refer pain directly into the head. We incorporate soft tissue techniques like myofascial release and trigger point therapy to release this muscular tension and further reduce the painful inputs to the central nervous system.
• Nervous System Regulation: Chiropractic adjustments have been shown to have a modulating effect on the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. Since migraine is a disorder of nervous system hyperexcitability, therapies that promote autonomic balance can be inherently therapeutic.
• Functional Medicine and Nutritional Counseling: As a certified functional medicine practitioner, I work with patients to identify and eliminate dietary triggers (e.g., gluten, dairy, aged cheeses), correct nutrient deficiencies (like magnesium or Vitamin B2), and support gut health. This biochemical optimization complements the structural work and the pharmacological interventions prescribed by Dr. Cardenas.

By integrating chiropractic care, we are not just treating the head; we are addressing the entire structural and neurological framework that supports it. This approach, combined with the medical and functional medicine strategies discussed, allows us to create a truly holistic and synergistic treatment plan that attacks migraine from all possible angles, moving patients toward a life defined not by their pain, but by their potential.

References

Ailani, J., Burch, R. C., & Robbins, M. S. (2021). The American Headache Society consensus statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain, 61(7), 1021-1039.

Allergan. (2017). PREEMPT (Phase 3 Research Evaluating Migraine Prophylaxis Therapy) trial design. [Clinical trial protocol]. Allergan plc.

American Headache Society. (2024). The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. Headache: The Journal of Head and Face Pain, 64(1), 1–20.

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).

Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache: The Journal of Head and Face Pain, 50(6), 921–936.

Edvinsson, L., Haanes, K. A., & Warfvinge, K. (2018). Does CGRP play a role in migraine pathogenesis?. Nature Reviews Neurology, 14(6), 338-350.

Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of migraine: A disease of the brain. Physiological Reviews, 97(2), 553–622.

Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211.

Jimenez, A. (n.d.). Clinical Observations and Professional Profile. Wellness Doctor RX. Retrieved August 20, 2026.

Jimenez, A. (n.d.). Dr. Alex Jimenez. LinkedIn. Retrieved August 20, 2026.

Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Goadsby, P. J., & Fischell, C. M. (2003). A self-administered screener for migraine in primary care: The ID Migraine™ validation study. Neurology, 61(3), 375–382.

National Headache Foundation. (2022). National Headache Foundation Position Statement on Preventive Migraine Treatment. Retrieved from https://headaches.org/resources/

Olesen, J., Burstein, R., Ashina, M., & Tfelt-Hansen, P. (2009). Origin of pain in migraine: evidence for peripheral sensitization. The Lancet Neurology, 8(7), 679-690.

Sacco, S., Bendtsen, L., Ashina, M., Reuter, U., Terwindt, G., Mitsikostas, D. D., & Martelletti, P. (2019).European Headache Federation guideline on the use of monoclonal antibodies acting on thecalcitonin gene-related peptide or its receptor for migraine prevention. The Journal of Headache and Pain, 20(1), 6.

Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012). Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology, 78(17), 1337–1345.

U.S. Food and Drug Administration. (2026). FDA Drug Safety Communication: Reports of Hypertension and Raynaud’s Phenomenon with CGRP Antagonists. FDA.gov.

SEO Tags: migraine diagnosis, migraine treatment, chronic migraine, episodic migraine, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso chiropractor, integrative chiropractic care, functional medicine, personal injury care, CGRP antagonists, gepants, rimegepant, ubrogepant, atogepant, ditans, lasmiditan, monoclonal antibodies, eptinezumab, fremanezumab, erenumab, galcanezumab, OnabotulinumtoxinA, Botox for migraines, medication overuse headache, migraine prevention, headache pathophysiology, SNOOP mnemonic, ID Migraine, tension-type headache, cortical spreading depression, central sensitization, trigeminovascular system, neurogenic inflammation, trigemino-cervical complex, serotonin, SNARE complex, SNAP-25, stratified care, evidence-based medicine, nurtec, qulipta, hypertension, Raynaud’s phenomenon, clinical pearls